Cellosaurus MDA-MB-435 (CVCL_0417)

Cell line name MDA-MB-435
Synonyms MDA-MB435; MDAMB435; MDA.MB.435; MDA-435; MDA 435; MDA435
Accession CVCL_0417
Resource Identification Initiative To cite this cell line use: MDA-MB-435 (RRID:CVCL_0417)
Comments Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=17004106, PubMed=20143388; PubMed=28940260). Originally thought to originate from a breast carcinoma. See also PubMed=19549886 for a dissenting but incorrect view that states that M14 is a breast cancer cell line.
Part of: NCI60 cancer cell line panel.
Doubling time: 25.8 hours (NCI-DTP).
Sequence variation: Heterozygous for BRAF p.Val600Glu (PubMed=17088437).
Sequence variation: Heterozygous for TP53 p.Gly266Glu (PubMed=17088437).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: MDA-MB-43; Occasionally.
Disease Amelanotic melanoma (NCIt: C3802)
Derived from metastatic site: Subcutaneous; right buttock.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1395 (M14)
Children: CVCL_0124 (435.eB); CVCL_B057 (M4A4); CVCL_J435 (MDA 435TR); CVCL_R957 (MDA-MB-435-BAG); CVCL_B055 (MDA-MB-435-LCC15); CVCL_4Y10 (MDA-MB-435-Luc#1); CVCL_6684 (MDA-MB-435HGF); CVCL_0622 (MDA-MB-435S); CVCL_1910 (MDA-N); CVCL_IN99 (MDA435/LCC6); CVCL_B064 (NM2C5)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11
D13S31712
D16S53913
D18S5113,17 (DOI=10.4172/2157-7145.S2-005; PubMed=19372543)
13 (PubMed=25877200)
D19S43314
D21S1130
D2S133819,24
D3S135814
D5S81811,12 (DOI=10.4172/2157-7145.S2-005; PubMed=19372543)
12 (PubMed=25877200)
D7S8208,10
D8S117913
FGA21
Penta D9,11
Penta E10,12
TH016,7
TPOX8,11
vWA16,18
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://dtp.cancer.gov/discovery_development/nci-60/mda-mb-435.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=51
http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/mda-mb-435.htm
http://iclac.org/wp-content/uploads/Cross-Contaminations-v8_0.pdf
https://www.ncbi.nlm.nih.gov/pubmed/25902968#cm25902968_13561
Publications

PubMed=730202; DOI=10.1007/BF02616120
Cailleau R.M., Olive M., Cruciger Q.V.J.
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
In Vitro 14:911-915(1978)

PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1
Satya-Prakash K.L., Pathak S., Hsu T.C., Olive M., Cailleau R.M.
Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes.
Cancer Genet. Cytogenet. 3:61-73(1981)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

PubMed=11044355; DOI=10.1054/bjoc.2000.1458
Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C., Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Molecular cytogenetic analysis of breast cancer cell lines.
Br. J. Cancer 83:1309-1317(2000)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=17004106; DOI=10.1007/s10549-006-9392-8
Rae J.M., Creighton C.J., Meck J.M., Haddad B.R., Johnson M.D.
MDA-MB-435 cells are derived from M14 melanoma cells -- a loss for breast cancer, but a boon for melanoma research.
Breast Cancer Res. Treat. 104:13-19(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=19549886; DOI=10.1158/0008-5472.CAN-09-1528
Chambers A.F.
MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?
Cancer Res. 69:5292-5293(2009)

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

DOI=10.4172/2157-7145.S2-005
Fang R., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M., Hart R.P., Furtado M.R.
STR profiling of human cell lines: challenges and possible solutions to the growing problem.
J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24162158; DOI=10.1007/s10549-013-2743-3
Prat A., Karginova O., Parker J.S., Fan C., He X., Bixby L., Harrell J.C., Roman E., Adamo B., Troester M., Perou C.M.
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Breast Cancer Res. Treat. 142:237-255(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

DOI=10.1038/npjbcancer.2015.2
Prasad V.V.T.S., Gopalan R.O.G.
Continued use of MDA-MB-435, a melanoma cell line, as a model for human breast cancer, even in year, 2014.
Npj Breast Cancer 1:15002-15002(2015)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28940260; DOI=10.1002/ijc.31067
Korch C., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M., Robinson S., Storts D., Turner J.A., Wang Y., Burnett E.C., Healy L., Kniss D., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A., Capes-Davis A.
Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
Int. J. Cancer 0:0-0(2017)

Cross-references
Cell line collections ATCC; CRL-12583 - Discontinued
NCI-DTP; MDA-MB-435
Cell line databases/resources CCRID; 3111C0001CCC000351
SKY/M-FISH/CGH; 2816
TOKU-E; 3544
Ontologies BTO; BTO:0001567
EFO; EFO_0001213
MCCL; MCC:0000314
Biological sample resources BioSample; SAMN03151832
BioSample; SAMN03470861
Chemistry resources ChEMBL-Cells; CHEMBL3307686
ChEMBL-Targets; CHEMBL614697
Gene expression databases GEO; GSM2095
GEO; GSM50203
GEO; GSM50265
GEO; GSM206523
GEO; GSM274648
GEO; GSM274649
GEO; GSM344352
GEO; GSM344402
GEO; GSM750814
GEO; GSM783965
GEO; GSM799354
GEO; GSM799417
GEO; GSM844589
GEO; GSM844590
GEO; GSM847037
GEO; GSM1008908
GEO; GSM1153424
GEO; GSM1181294
GEO; GSM1181337
GEO; GSM1215267
GEO; GSM1670084
GEO; GSM2124670
Polymorphism and mutation databases Cosmic; 687496
Cosmic; 875879
Cosmic; 905988
Cosmic; 974069
Cosmic; 974236
Cosmic; 991325
Cosmic; 1000131
Cosmic; 1010930
Cosmic; 1044219
Cosmic; 1092614
Cosmic; 1175834
Cosmic; 1176643
Cosmic; 1219445
Cosmic; 1305366
Cosmic; 1312349
Cosmic; 1477425
Cosmic; 1524346
Cosmic; 1571794
Cosmic; 1945861
Cosmic; 1998456